RFM
TEVA icon

Royal Fund Management’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Royal Fund Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-400
Closed -$3K – 524
2020
Q1 		$3K Hold
400
– – ﹤0.01% 473
2019
Q4 		$3K Hold
400
– – ﹤0.01% 527
2019
Q3 		$2K Buy
+400
New +$3.06K ﹤0.01% 532

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Royal Fund Management's TEVA Position: Q2 2020 in Review

Royal Fund Management sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q2 2020, closing a stake of 400 shares — an estimated $3K sold.

Royal Fund Management first reported a position in TEVA in Q3 2019 and held it in 3 quarters. The position peaked at $3K in Q1 2020. 456 funds tracked by Wall St. Rank hold TEVA as of Q2 2020.

  • Royal Fund Management reported no remaining Teva Pharmaceutical Industries Limited position as of Q2 2020 after selling out during the quarter.
  • Royal Fund Management sold 400 Teva Pharmaceutical Industries Limited shares in Q2 2020, an estimated $3K.
  • Royal Fund Management first reported a position in Teva Pharmaceutical Industries Limited in Q3 2019 and held it in 3 quarters.
  • Royal Fund Management's Teva Pharmaceutical Industries Limited position peaked at $3K in Q1 2020.
  • 456 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q2 2020.

Based on Royal Fund Management's 13F filing for Q2 2020, filed 6 Aug 2020.